Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 2.03

Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 0.95

Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics (2009) 0.89

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry (2003) 0.87

Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol (2005) 0.87

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One (2012) 0.86

Multiple sclerosis and pregnancy. Postgrad Med J (2002) 0.86

Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler (2009) 0.85

Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology (2011) 0.84

The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol (2004) 0.83

Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80

Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. Hum Brain Mapp (2012) 0.80

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 0.75

New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67

Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44

Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11

Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61

Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68

Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67

Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75

Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain (2003) 3.65

The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31

Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25

The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15

Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11

Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain (2003) 3.04

The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67

Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64

Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61

Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56

Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54

Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54

Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53

Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50

Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47

Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44

The persistent vegetative state. BMJ (1995) 2.35

Management of acute optic neuritis. Lancet (2002) 2.33

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29

Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23

Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17

Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11

The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07

The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05

The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil (1995) 2.04

Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02

Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01

Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01

Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00

Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00

Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97

The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95

Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93

MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90

Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87

Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82

Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80

Primary progressive multiple sclerosis. Brain (1997) 1.80

Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80

A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76

The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol (1997) 1.73

B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73